Mobile

A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fix...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-001128-35

A 12-week randomised, evaluator-masked, parallel-group, multinational, multi-centre study comparing the efficacy and safety of the fixed combination of latanoprost and timolol (XalacomTM) with the fixed combination of dorzolamide and timolol (Cosopt®) in subjects with open-angle glaucoma or ocular hypertension

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To demonstrate the mean diurnal IOP reducing effect of Xalacom™ administered once daily in the evening is non-inferior to that of Cosopt administered twice daily from Baseline to Week 12.

Critère d'inclusion

  • Open-angle glaucoma

Liens